David A. Siegel Imara Inc. Transaction History

Two Sigma Advisers, LP

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	BUY	$3.73 - $5.2 $95,861 - $133,640	25,700 New	25,700 $105,000
Q2 2022 Aug 15, 2022	SELL	$0.99 - $1.87 $100,188 - $189,244	-101,200 Reduced 35.63%	182,800 $223,000
Q1 2022 May 16, 2022	BUY	$1.15 - $2.41 $30,129 - $63,142	26,200 Added 10.16%	284,000 $534,000
Q4 2021 Feb 14, 2022	SELL	$2.25 - $4.05 $6,300 - $11,340	-2,800 Reduced 1.07%	257,800 $580,000
Q3 2021 Nov 15, 2021	BUY	$4.08 - $7.83 $1.06 Million - $2.04 Million	260,600 New	260,600 $1.06 Million
Q2 2021 Aug 16, 2021	SELL	$6.78 - $9.04 $111,870 - $149,160	-16,500 Closed	0 $0
Q1 2021 May 17, 2021	BUY	$8.18 - $23.98 $134,970 - $395,670	16,500 New	16,500 $139,000

104K

170K

Ticker IMRA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 26,287,300
Market Cap $552M
Description
IMARA Inc., a clinical-stage biopharmaceutical company, develops and commercializes therapeutics for patients with rare genetic disorders of hemoglobin. Its lead product candidate is IMR-687, an oral and once-a-day therapeutic that is in Phase 2b clinical trials for the treatment of sickle cell disease and ß-thalassemia. The company also develop...

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.